151309-48-7

Basic information

• Product Name: 2,2-Difluoroheptacosanoic acid, ethyl(ester)
• Synonyms: 2,2-Difluoroheptacosanoic acid, ethyl(ester)
• CAS NO: 151309-48-7
• Molecular Formula: C₁₆H₃₀F₂O₂
• Molecular Weight: 292.4
• Mol File: 151309-48-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,2-Difluoroheptacosanoic acid, ethyl(ester)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-Difluoroheptacosanoic acid, ethyl(ester)(151309-48-7)
• EPA Substance Registry System: 2,2-Difluoroheptacosanoic acid, ethyl(ester)(151309-48-7)

Safety Data

• Hazardous Substances Data: 151309-48-7(Hazardous Substances Data)

Upstream product

• 112-41-4 1-dodecene 
• 667-27-6 Ethyl bromodifluoroacetate 
• 66553-46-6 (1E)-1-iodododec-1-ene 
• 765-03-7 1-dodecyne 
• 160941-12-8 2-carbethoxy-2-dodecyl-1,3-dithiane 
• 143-15-7 1-dodecylbromide 
• 160941-13-9 2-oxo-tetradecanoic acid ethyl ester 

Relevant articles and documents

Discovery of a Fluorinated Enigmol Analog with Enhanced in Vivo Pharmacokinetic and Anti-Tumor Properties

The orally bioavailable 1-deoxy-sphingosine analog, Enigmol, has demonstrated anticancer activity in numerous in vivo settings. However, as no Enigmol analog with enhanced potency in vitro has been identified, a new strategy to improve efficacy in vivo by increasing tumor uptake was adopted. Herein, synthesis and biological evaluation of two novel fluorinated Enigmol analogs, CF3-Enigmol and CF2-Enigmol, are reported. Each analog was equipotent to Enigmol in vitro, but achieved higher plasma and tissue levels than Enigmol in vivo. Although plasma and tissue exposures were anticipated to trend with fluorine content, CF2-Enigmol absorbed into tissue at strikingly higher concentrations than CF3-Enigmol. Using mouse xenograft models of prostate cancer, we also show that CF3-Enigmol underperformed Enigmol-mediated inhibition of tumor growth and elicited systemic toxicity. By contrast, CF2-Enigmol was not systemically toxic and demonstrated significantly enhanced antitumor activity as compared to Enigmol.

Sphingosine Analogs, Compositions, and Methods Related Thereto

The disclosure relates to compounds, pharmaceutical compositions, and methods of treating or preventing disease. In certain embodiments, the disclosure relates to methods of treating an infection or cancer comprising administering a pharmaceutical composition disclosed herein to a subject in need thereof. In a typical embodiment, one administers a pharmaceutical composition comprising sphingosine or a sphingosine analog to a subject at risk for, exhibiting symptoms of or diagnosed with a malaria infection.

Spicamycin derivatives and their use as anticancer agents

Spicamycin derivative represented by the formula (I) or a salt thereof: STR1 wherein R represents specific diverse substituents, for example, a linear alkadienyl having from 11 to 13 carbon atoms, and R1 and R2 respectively represent H or OH. Examples of specific compounds are 6-[4'-N-(N'-trans,trans 2,4-tridecadienoylglycyl)spicaminyl-amino]purine, and 6-[4'-N-(N'-trans,trans-2,4 dodecadienyoly glycyl) spicaminyl-amino]purine. Comopunds according to this invention are useful as a pharmaceutical for inhibition of a tumor, for example, human colon cancer.